While Krabbe disease treatments are advancing, accessibility remains a critical challenge. High costs, limited production, and regional disparities in healthcare infrastructure mean many patients—particularly in low- and middle-income countries (LMICs)—cannot access life-saving therapies. Addressing these gaps is essential for the Krabbe disease treatment market to realize its full potential and ensure equitable care.

Traditional HSCT, though available, requires specialized facilities and donor matching, limiting access. A 2023 INSL survey found only 15% of Krabbe patients in LMICs receive HSCT, compared to 60% in high-income regions. Emerging therapies, like gene therapies, face even steeper barriers: cost alone prevents 80% of families globally from consideration (2024 Healthcare Access Report). To explore these disparities, the Krabbe Treatment Accessibility section in Market Research Future’s report examines pricing strategies, distribution logistics, and policy interventions.

Efforts to improve accessibility include pricing reforms and partnerships. In 2024, BioMarin announced a tiered pricing model for its Krabbe ERT, reducing costs by 60% in LMICs. Pharma firms are also collaborating with NGOs; a 2024 alliance between GenoCure and the International Society for Stem Cell Research (ISSCR) aims to build HSCT centers in India and Brazil. These initiatives have already increased access: 2024 data shows a 25% rise in LMIC patients receiving approved therapies compared to 2022.

Despite progress, challenges persist. Complex manufacturing processes limit ERT and gene therapy supply, while regulatory delays in LMICs slow approval. Market Research Future estimates that without targeted interventions, 40% of Krabbe patients will still lack access by 2030. Prioritizing affordability and infrastructure investment will be key to transforming the market from one of exclusivity to one of widespread impact.